reassuring cardiac safety profile of pharmaceutical cannabidiol formulation
A recent study reveals that a pharmaceutical cannabidiol formulation demonstrates a favorable safety profile, including no significant cardiac safety concerns, in patients with cardiovascular risk factors. Ongoing trials continue to explore its potential benefits.
Recent research presented at Heart Failure 2025 has demonstrated that a pharmaceutically manufactured cannabidiol (CBD) formulation exhibits a strong safety profile, including no significant cardiac safety concerns. This study evaluated the overall safety, tolerability, and cardiac effects of CBD in patients with increased cardiovascular risk who were hospitalized for non-critical COVID-19. The trial included 89 adult patients, with participants randomized to receive either the CBD formulation, titrated up to 7.5 mg/kg twice daily, or a placebo. Despite early termination of the trial due to patient recruitment challenges, safety outcomes from the enrolled cohort showed minimal adverse effects.
The incidences of serious adverse events and treatment-related adverse effects were comparable between groups, with no deaths reported in the CBD group and two in the placebo group, both due to respiratory failure. Importantly, cardiovascular safety indicators, including ECG measurements and QTc intervals, remained stable in the CBD group, with minimal changes from baseline. Cardiac disorders were reported in 9% of patients in both groups, and only one patient in the CBD group experienced mild QTc prolongation.
Dr. Leslie Cooper from the Mayo Clinic highlighted that CBD was well tolerated overall and noted the low, comparable rates of cardiac side effects. These reassuring findings support ongoing larger trials assessing the efficacy and safety of CBD for cardiovascular inflammation, such as the Phase II ARCHER trial for myocarditis and the Phase III MAVERIC trial for recurrent pericarditis, expected to report results in 2025 and 2026 respectively. The emerging evidence suggests that pharmaceutical CBD offers a promising, safe adjunct in managing inflammatory heart conditions.
Source: https://medicalxpress.com/news/2025-05-cardiac-safety-pharmaceutically-cannabidiol.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
The Importance of Discussing Sexual Health After Gynecological Cancer Treatment
Open communication about sexual health post-gynecological cancer treatment is essential for survivors' well-being. Learn how healthcare providers can support emotional and physical intimacy through respectful conversations.
Less Than Half of Critical Trauma Patients Are Transferred to Level I Trauma Centers
A new study reveals that less than 50% of severely injured trauma patients are transferred to specialized Level I centers, highlighting gaps in the US trauma system and the need for better triage protocols.
Breakthrough in HIV Cure Strategy: Key Protein Revives Hidden Virus Reservoirs
Researchers have discovered that targeting the protein BRD9 can reactivate dormant HIV-1, paving the way for new 'shock and kill' treatment strategies to eliminate the virus reservoirs in infected cells.
How Positive Memories of Drug Use Can Contribute to AddictionPersistence
Memories of positive drug experiences reinforce addiction by activating neural circuits, making relapse more likely. Understanding these mechanisms offers hope for new treatments to combat substance use disorders.